Sanofi GCVRZ 深 沪
等待开盘 06-24 09:30:00 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection
Sanofi SA (NASDAQ:SNY) secured two regulatory milestones this week, with European authorities approving Cenrifki for non-relapsing secondary progressive multiple sclerosis (nrSPMS) and Japanese regulators authorizing Wayrilz for persistent and chronic immune thrombocytopenia. Read Also: Sanofi Trial...
今天 00:21
MacroGenics gains $24.5M payment from Sanofi for Tzield approval
Sanofi (SNY) is providing MacroGenics (MGNX) a $24.5M milestone payment following the recently approved additional indication of Tzield (teplizumab) to delay the decline in endogenous insulin producti...
06-23 05:13
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
While there are already several drugs already approved to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, Shalabh Gupta isn't fazed. As CEO of Unicycive Therapeutics...
06-22 21:56
Biggest stock movers Monday: APGE, GETY, and more
Stock futures were mixed Monday morning as investors monitored U.S.-Iran peace talks in Switzerland, which mediators noted are making "encouraging progress." The two sides have established a 60-day ro...
06-22 17:32
Apogee soars on AbbVie deal report; analysts bullish
Apogee Therapeutics (APGE) shares surged by as much as 56% in premarket trading on Monday after the Financial Times reported that AbbVie (ABBV) is close to acquiring the company in a deal valued at ne...
06-22 16:46
COUR Pharma closes $50 million Series B led by Lumira Ventures, Roche Venture Fund
COUR Pharma closes $50 million Series B led by Lumira Ventures, Roche Venture Fund COUR Pharma, a clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases, closed a USD 50 million Series B round. The financing was led by Lumira Capital Investment Manageme
06-19 22:57
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma June 19 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION APPROVED IN JAPAN FOR PATIENTS WITH MULTIPLE MYELOMA APPROVAL BASED ON IRAKLIA PHASE 3 STUDY SHOWING
06-19 18:33
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny By Christy Santhosh and Mariam Sunny June 18 (Reuters) - The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's MRNA.O flu vaccine outweigh its risks in older adults, after regulators rev
06-18 18:00
药物受理最新动态：Sanofi-Aventis Recherche & DéveloppementIsatuximab注射液（皮下注射）补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年6月17日，Sanofi-Aventis Recherche & Développement的Isa...
06-17 20:15
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients
The U.S. Food and Drug Administration has granted accelerated approval to Sanofi SA’s (NASDAQ:SNY) Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in children ages 8 to 17 who have been recently diagnosed with stage 3 type 1 diabetes (T1D). The decision expands the the...
06-16 01:15
